FDA Approval. After due investigation, (i) the Company and MCI have no reason to believe that the United States Food and Drug Administration ("FDA") will ultimately prohibit the marketing, sale, license or use in the United States of any of the Products and (ii) neither the Company nor MCI know of any product or process which the FDA has prohibited from being marketed or used in the United States which in function and composition is substantially similar to any Product.
Appears in 2 contracts
Sources: Preferred Stock Purchase Agreement (Iomed Inc), Preferred Stock Purchase Agreement (Iomed Inc)